BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21391862)

  • 1. Drug delivery strategies for Alzheimer's disease treatment.
    Di Stefano A; Iannitelli A; Laserra S; Sozio P
    Expert Opin Drug Deliv; 2011 May; 8(5):581-603. PubMed ID: 21391862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?
    Imbimbo BP; Panza F; Frisardi V; Solfrizzi V; D'Onofrio G; Logroscino G; Seripa D; Pilotto A
    Expert Opin Investig Drugs; 2011 Mar; 20(3):325-41. PubMed ID: 21222550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
    Sevilla C; Jiménez Caballero PE; Alfonso V; González-Adalid M
    Dement Geriatr Cogn Disord; 2009; 28(3):196-205. PubMed ID: 19738386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds.
    Czirr E; Weggen S
    Neurodegener Dis; 2006; 3(4-5):298-304. PubMed ID: 17047371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease].
    Franke AG; Lieb K; Fellgiebel A
    Fortschr Neurol Psychiatr; 2009 Jun; 77(6):326-33. PubMed ID: 19504422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Alzheimer's disease: from brain lesions to new drugs].
    Forette F; Hauw JJ
    Bull Acad Natl Med; 2008 Feb; 192(2):363-78; discussion 378-80. PubMed ID: 18819689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic options in Alzheimer's disease.
    Moreira PI; Zhu X; Nunomura A; Smith MA; Perry G
    Expert Rev Neurother; 2006 Jun; 6(6):897-910. PubMed ID: 16784412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we do better in developing new drugs for Alzheimer's disease?
    Gauthier S; Scheltens P
    Alzheimers Dement; 2009 Nov; 5(6):489-91. PubMed ID: 19896588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential therapeutic agents against Alzheimer's disease from natural sources.
    Park SY
    Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in Alzheimer's disease drug discovery: an update.
    Williams M
    Curr Opin Investig Drugs; 2009 Jan; 10(1):23-34. PubMed ID: 19127484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanotherapeutics for Alzheimer's disease (AD): Past, present and future.
    Fazil M; Shadab ; Baboota S; Sahni JK; Ali J
    J Drug Target; 2012 Feb; 20(2):97-113. PubMed ID: 22023651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of Alzheimer's disease].
    López OL; Becker JT
    Rev Neurol; 2002 Nov 1-15; 35(9):850-9. PubMed ID: 12436384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alzheimer's disease: therapeutic perspectives].
    Dubois B; De Souza L; Allali G; Kalafat M; Sarazin M
    Bull Acad Natl Med; 2008 Feb; 192(2):333-42; discussion 343-4. PubMed ID: 18819687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease: clinical treatment options.
    Reichman WE
    Am J Manag Care; 2000 Dec; 6(22 Suppl):S1125-32; discussion S1133-8. PubMed ID: 11142177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.